Moleculin Biotech, Inc. (MBRX) Stock

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing innovative drug candidates aimed at treating highly resistant tumors and viral infections. Leading its portfolio is Annamycin, currently undergoing Phase 1/2 studies for relapsed or refractory acute myeloid leukemia (AML) and lung metastases. The company's flagship immune and transcription modulator, WP1066, is in Phase I trials for brain tumors, pediatric brain tumors, pancreatic cancer, and other malignancies. Additionally, Moleculin Biotech develops WP1220, a WP1066 analog for topical treatment of cutaneous T-cell lymphoma, and WP1122, targeted at glioblastoma multiforme and COVID-19.

Headquartered in Houston, Texas, Moleculin Biotech, Inc. was founded in 2015 with a mission to pioneer transformative treatments in oncology and infectious diseases. The company distinguishes itself through strategic partnerships and collaborations with esteemed institutions such as MD Anderson Cancer Center, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. These alliances bolster Moleculin Biotech's research capabilities and enhance its potential to deliver novel therapies that address critical unmet medical needs.

Driven by a commitment to scientific innovation, Moleculin Biotech, Inc. remains at the forefront of pharmaceutical research and development. Through its diverse pipeline and collaborative efforts, the company strives to make significant advancements in oncology and virology, offering new hope to patients worldwide.